Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 3/20 | 0.36 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | ALPL | P05186 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18723265 | 0.80 | L3MBTL1 (0.46) | L3MBTL1GAAKDM4ESMN1; SMN2RAB9A | |
| SCHEMBL27305866 | 0.78 | L3MBTL1 (0.42) | L3MBTL1GAASMN1; SMN2POLBIRAK4 | |
| SCHEMBL799376 | 0.76 | HSP90AB1 (0.45) | L3MBTL1GAAKDM4ESMN1; SMN2RAB9A | |
| SCHEMBL18256161 | 0.76 | IRAK4 (0.48) | IRAK4 | |
| SCHEMBL20662116 | 0.69 | PDE10A (0.48) | POLBPDE10AIRAK4 | |
| SCHEMBL23844208 | 0.69 | FLT1 (0.39) | GAANPC1 | |
| SCHEMBL7981206 | 0.66 | BRD4 (0.40) | GAAKDM4ESMN1; SMN2BRD4LMNA | |
| SCHEMBL17966581 | 0.66 | L3MBTL1 (0.42) | L3MBTL1GAAKDM4ESMN1; SMN2POLB | |
| SCHEMBL799162 | 0.65 | MAPT (0.44) | L3MBTL1GAAKDM4ESMN1; SMN2POLB | |
| SCHEMBL17966580 | 0.65 | L3MBTL1 (0.41) | L3MBTL1GAAKDM4ESMN1; SMN2RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220169631-A9 | TAIRE FAMILY KINASE INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-06-02 | — | — | US | disclosed |
| US-20210292299-A1 | TAIRE FAMILY KINASE INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220169631-A9 | TAIRE FAMILY KINASE INHIBITORS AND USES THEREOF | CDK14, CDK16, CDK19 | L3MBTL1 761/4885GAA 2839/4885KDM4E 2531/4885 |
| US-20210292299-A1 | TAIRE FAMILY KINASE INHIBITORS AND USES THEREOF | CDK14, CDK16, CDK19 | L3MBTL1 761/4885GAA 2839/4885KDM4E 2531/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.